Cargando…

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

Detalles Bibliográficos
Autores principales:	Pender, Michael P., Csurhes, Peter A., Smith, Corey, Douglas, Nanette L., Neller, Michelle A., Matthews, Katherine K., Beagley, Leone, Rehan, Sweera, Crooks, Pauline, Hopkins, Tracey J., Blum, Stefan, Green, Kerryn A., Ioannides, Zara A., Swayne, Andrew, Aftab, Blake T., Hooper, Kaye D., Burrows, Scott R., Thompson, Kate M., Coulthard, Alan, Khanna, Rajiv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2020
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605530/ https://www.ncbi.nlm.nih.gov/pubmed/33055421 http://dx.doi.org/10.1172/jci.insight.144624

Ejemplares similares

Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis
por: Pender, Michael P, et al.
Publicado: (2014)

Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy
por: Ioannides, Zara A., et al.
Publicado: (2021)

Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis
por: Ioannides, Zara A, et al.
Publicado: (2021)

T‐cell adoptive immunotherapy for BK nephropathy in renal transplantation
por: Jahan, Sadia, et al.
Publicado: (2020)

Defective T-cell control of Epstein–Barr virus infection in multiple sclerosis
por: Pender, Michael P, et al.
Publicado: (2017)

Defective T-cell control of Epstein–Barr virus infection in multiple sclerosis
por: Pender, Michael P, et al.
Publicado: (2017)

Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement
por: Smith, Corey, et al.
Publicado: (2015)

Decreased T cell reactivity to Epstein–Barr virus infected lymphoblastoid cell lines in multiple sclerosis
por: Pender, M P, et al.
Publicado: (2009)

CD8 T cell deficiency impairs control of Epstein–Barr virus and worsens with age in multiple sclerosis
por: Pender, Michael P, et al.
Publicado: (2011)

'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
por: Sinha, Debottam, et al.
Publicado: (2021)

Decreased CD8(+ )T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes
por: Pender, Michael P, et al.
Publicado: (2011)

SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants
por: Panikkar, Archana, et al.
Publicado: (2022)

Rapid whole‐blood assay to detect SARS‐CoV‐2‐specific memory T‐cell immunity following a single dose of AstraZeneca ChAdOx1‐S COVID‐19 vaccine
por: Lineburg, Katie E, et al.
Publicado: (2021)

Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response
por: Smith, Corey, et al.
Publicado: (2017)

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies
por: Bar-Or, Amit, et al.
Publicado: (2020)

Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients
por: Bhatt, Kunal H., et al.
Publicado: (2020)

Correction: Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients
por: Bhatt, Kunal H., et al.
Publicado: (2022)

Ablation of CD8(+) T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3
por: Swaminathan, Srividhya, et al.
Publicado: (2022)

Deficiency of CD8(+) effector memory T cells is an early and persistent feature of multiple sclerosis
por: Pender, Michael P, et al.
Publicado: (2014)

Epstein–Barr virus and multiple sclerosis: potential opportunities for immunotherapy
por: Pender, Michael P, et al.
Publicado: (2014)

Adoptive T‐cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis
por: Smith, Corey, et al.
Publicado: (2023)

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: (Trends in Molecular Medicine, 26:3 p:296-310, 2020)
por: Bar-Or, Amit, et al.
Publicado: (2021)

Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation
por: Holmes-Liew, Chien-Li, et al.
Publicado: (2015)

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
por: Smith, Corey, et al.
Publicado: (2021)

Molecular signature of Epstein-Barr virus infection in MS brain lesions
por: Moreno, Monica A., et al.
Publicado: (2018)

CD8(+) T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with selective seasonal coronaviruses
por: Lineburg, Katie E., et al.
Publicado: (2021)

Pre-clinical development of T-cell immunotherapy for covid-19
por: Smith, C., et al.
Publicado: (2021)

Impact of pre‐therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV‐specific T‐cell therapy
por: Walker, David G, et al.
Publicado: (2019)

Endogenous Presentation of CD8(+) T Cell Epitopes from Epstein-Barr Virus–encoded Nuclear Antigen 1
por: Tellam, Judy, et al.
Publicado: (2004)

Rapid detection of SARS‐CoV‐2‐specific memory T‐cell immunity in recovered COVID‐19 cases
por: Lineburg, Katie E, et al.
Publicado: (2020)

The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis
por: Pender, Michael P.
Publicado: (2011)

Hypothesis: bipolar disorder is an Epstein–Barr virus‐driven chronic autoimmune disease – implications for immunotherapy
por: Pender, Michael P
Publicado: (2020)

Immunotherapy: ADOPTIVE T CELL IMMUNOTHERAPY FOR SARS-COV-2
por: Henden, A., et al.
Publicado: (2023)

Epstein-Barr Virus Associated Modulation of Wnt Pathway Is Not Dependent on Latent Membrane Protein-1
por: Webb, Natasha, et al.
Publicado: (2008)

Interleukin-6 Gene Promoter-572 C Allele may Play a Role in Rate of Disease Progression in Multiple Sclerosis
por: Yan, Jun, et al.
Publicado: (2012)

CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis
por: Pender, Michael P.
Publicado: (2012)

Proteome‐wide analysis of T‐cell response to BK polyomavirus in healthy virus carriers and kidney transplant recipients reveals a unique transcriptional and functional profile
por: Ambalathingal, George R, et al.
Publicado: (2020)

Limited Recognition of Highly Conserved Regions of SARS-CoV-2
por: Swaminathan, Srividhya, et al.
Publicado: (2022)

Recent Advances on the Possible Neuroprotective Activities of Epstein-Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
por: Wynne, Alicia, et al.
Publicado: (2010)

Cellular immune therapy for viral infections in transplant patients
por: Khanna, Rajiv, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cb8hecfujevsv3ssdu4rc013fu